SI2782997T1 - A rolling lentiviral vector manufacturing system compatible with industrial pharmaceutical applications - Google Patents
A rolling lentiviral vector manufacturing system compatible with industrial pharmaceutical applications Download PDFInfo
- Publication number
- SI2782997T1 SI2782997T1 SI201231258T SI201231258T SI2782997T1 SI 2782997 T1 SI2782997 T1 SI 2782997T1 SI 201231258 T SI201231258 T SI 201231258T SI 201231258 T SI201231258 T SI 201231258T SI 2782997 T1 SI2782997 T1 SI 2782997T1
- Authority
- SI
- Slovenia
- Prior art keywords
- transfection
- plasmid
- culture
- cells
- pei
- Prior art date
Links
- 239000013598 vector Substances 0.000 title claims abstract 9
- 238000004519 manufacturing process Methods 0.000 title claims abstract 6
- 239000013612 plasmid Substances 0.000 claims 16
- 238000000034 method Methods 0.000 claims 13
- 210000004027 cell Anatomy 0.000 claims 10
- 238000001890 transfection Methods 0.000 claims 9
- 229920002873 Polyethylenimine Polymers 0.000 claims 7
- 238000004113 cell culture Methods 0.000 claims 5
- 241000713666 Lentivirus Species 0.000 claims 3
- 239000001963 growth medium Substances 0.000 claims 3
- 238000003306 harvesting Methods 0.000 claims 3
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 claims 3
- 239000000725 suspension Substances 0.000 claims 3
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 claims 2
- 108010027225 gag-pol Fusion Proteins Proteins 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 1
- 108091034117 Oligonucleotide Proteins 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 101710150344 Protein Rev Proteins 0.000 claims 1
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 208000015181 infectious disease Diseases 0.000 claims 1
- 230000002458 infectious effect Effects 0.000 claims 1
- 239000002609 medium Substances 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 239000012679 serum free medium Substances 0.000 claims 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 claims 1
- 235000017557 sodium bicarbonate Nutrition 0.000 claims 1
- 238000003146 transient transfection Methods 0.000 claims 1
- 238000011238 DNA vaccination Methods 0.000 abstract 1
- 238000001415 gene therapy Methods 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/02—Recovery or purification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/10051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/15011—Lentivirus, not HIV, e.g. FIV, SIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16051—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Plant Pathology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161563566P | 2011-11-24 | 2011-11-24 | |
| EP11306551 | 2011-11-24 | ||
| EP12795778.5A EP2782997B1 (en) | 2011-11-24 | 2012-11-26 | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
| PCT/EP2012/073645 WO2013076309A1 (en) | 2011-11-24 | 2012-11-26 | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SI2782997T1 true SI2782997T1 (en) | 2018-04-30 |
Family
ID=48469165
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SI201231258T SI2782997T1 (en) | 2011-11-24 | 2012-11-26 | A rolling lentiviral vector manufacturing system compatible with industrial pharmaceutical applications |
Country Status (20)
| Country | Link |
|---|---|
| US (3) | US20140315294A1 (en22) |
| EP (2) | EP2782997B1 (en22) |
| JP (2) | JP6280869B2 (en22) |
| CN (2) | CN109097398A (en22) |
| AU (1) | AU2012342355B2 (en22) |
| BR (1) | BR112014012600A2 (en22) |
| CA (1) | CA2856455C (en22) |
| CY (1) | CY1120103T1 (en22) |
| DK (1) | DK2782997T3 (en22) |
| ES (1) | ES2663815T3 (en22) |
| HR (1) | HRP20180424T1 (en22) |
| HU (1) | HUE036742T2 (en22) |
| LT (1) | LT2782997T (en22) |
| PL (1) | PL2782997T3 (en22) |
| PT (1) | PT2782997T (en22) |
| RS (1) | RS57066B1 (en22) |
| SG (1) | SG11201402584RA (en22) |
| SI (1) | SI2782997T1 (en22) |
| SM (1) | SMT201800174T1 (en22) |
| WO (1) | WO2013076309A1 (en22) |
Families Citing this family (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2782997B1 (en) | 2011-11-24 | 2018-01-10 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
| FR3010720B1 (fr) * | 2013-09-16 | 2017-08-11 | Genethon | Procede de production de virus enveloppes |
| FR3014901B1 (fr) | 2013-12-17 | 2017-06-09 | Genethon | Procede de purification de virus ou vecteurs viraux enveloppes |
| WO2015097650A1 (en) * | 2013-12-23 | 2015-07-02 | Theravectys | Lyophilized lentiviral vector particles, compositions and methods |
| GB201417042D0 (en) * | 2014-09-29 | 2014-11-12 | Fkd Therapies Oy | Method |
| EP4316500A3 (en) | 2015-05-13 | 2024-04-10 | CSL Behring Gene Therapy, Inc. | Bio-production of lentiviral vectors |
| CN105483092A (zh) * | 2015-10-10 | 2016-04-13 | 和元生物技术（上海）股份有限公司 | 一种中试化生产重组腺相关病毒的新技术 |
| SG11201806976UA (en) | 2016-02-23 | 2018-09-27 | Immune Design Corp | Multigenome retroviral vector preparations and methods and systems for producing and using same |
| CN109071594A (zh) * | 2016-04-14 | 2018-12-21 | 崔泽尔有限公司 | 具有恒流泵/管道系统的固定床生物反应器 |
| CN116144500A (zh) | 2016-04-14 | 2023-05-23 | 崔泽尔有限公司 | 具有恒流泵/管道系统的固定床生物反应器 |
| WO2018064584A1 (en) * | 2016-09-30 | 2018-04-05 | Life Technologies Corporation | Serum-free suspension system for lentiviral production |
| CN106867877A (zh) * | 2017-02-15 | 2017-06-20 | 昆明医科大学第二附属医院 | 一种密闭式慢病毒载体培养装置和培养方法 |
| US11674115B2 (en) | 2017-10-31 | 2023-06-13 | Global Life Sciences Solutions Usa Llc | Flexible bag |
| CN111727251B (zh) | 2017-11-21 | 2024-09-20 | 克里斯珀医疗股份公司 | 用于治疗常染色体显性色素性视网膜炎的材料和方法 |
| CA3084632A1 (en) | 2017-12-21 | 2019-06-27 | Crispr Therapeutics Ag | Materials and methods for treatment of usher syndrome type 2a |
| WO2019123430A1 (en) | 2017-12-21 | 2019-06-27 | Casebia Therapeutics Llp | Materials and methods for treatment of usher syndrome type 2a and/or non-syndromic autosomal recessive retinitis pigmentosa (arrp) |
| CN110317832B (zh) | 2018-03-28 | 2022-07-05 | 西比曼生物科技（香港）有限公司 | Gmp级规模化制备重组慢病毒载体的纯化制剂的方法 |
| CN110317791A (zh) * | 2018-03-29 | 2019-10-11 | 西比曼生物科技（香港）有限公司 | Gmp级无血清悬浮细胞大规模生产慢病毒的方法 |
| CN108866013B (zh) * | 2018-08-06 | 2021-03-23 | 武汉赛科成科技有限公司 | 一种大规模生产慢病毒的方法 |
| EP3854879A4 (en) * | 2018-09-20 | 2022-06-22 | National University Corporation Tokyo Medical and Dental University | METHOD OF INCREASING THE PRODUCTION OF LENTIVIRUS VECTORS |
| CN109401969B (zh) * | 2018-12-13 | 2024-02-02 | 珠海西格膜生物技术有限公司 | 一种细胞工厂的管道连接系统及其使用方法 |
| JP7333930B2 (ja) * | 2019-01-07 | 2023-08-28 | 独立行政法人国立高等専門学校機構 | ミミズ細胞の保存方法及びミミズ培養細胞の形質転換方法 |
| JP2022551219A (ja) | 2019-08-23 | 2022-12-08 | ロンザ ウォーカーズヴィル，インコーポレーテッド | レンチウイルスベクターの製造方法および構築物 |
| CN113122501B (zh) * | 2019-12-30 | 2023-06-16 | 重庆精准生物技术有限公司 | 适合大规模临床级病毒载体制备的培养基及其应用 |
| JP2023526348A (ja) * | 2020-05-15 | 2023-06-21 | アイヴェックスソル インコーポレイテッド | 細胞療法及び遺伝子療法のための安定したウイルスベクター産生細胞を産生するための組成物及び方法 |
| US20230220417A1 (en) * | 2020-05-26 | 2023-07-13 | Expression Therapeutics, Llc | Lentiviral System |
| KR20230126214A (ko) * | 2020-12-29 | 2023-08-29 | 지앙수 젠스크립트 프로바이오 바이오테크 컴퍼니 리미티드 | 고분산성 hek293t 세포주 및 이의 스크리닝 방법 |
| GB202100688D0 (en) * | 2021-01-19 | 2021-03-03 | Autolus Ltd | Process |
| US20240425880A1 (en) * | 2021-10-12 | 2024-12-26 | Jiangsu Genscript Probio Biotech Co., Ltd. | Hek293 cell line adapted to serum-free suspension culture and use thereof |
| CA3231011A1 (en) * | 2021-10-19 | 2023-04-27 | Amgen Inc. | Composition and methods for recombinant lentiviral production |
| EP4508198A1 (en) * | 2022-04-11 | 2025-02-19 | Adverum Biotechnologies, Inc. | Optimization of hek293 suspension platform for improved raav titers |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2722506B1 (fr) | 1994-07-13 | 1996-08-14 | Rhone Poulenc Rorer Sa | Composition contenant des acides nucleiques, preparation et utilisations |
| US6210922B1 (en) | 1998-11-30 | 2001-04-03 | National Research Council Of Canada | Serum free production of recombinant proteins and adenoviral vectors |
| US20030096414A1 (en) | 2001-03-27 | 2003-05-22 | Invitrogen Corporation | Culture medium for cell growth and transfection |
| AU2002348151A1 (en) | 2001-11-05 | 2003-05-19 | Genvec, Inc. | Viral vector production methods and compositions |
| GB0702695D0 (en) * | 2007-02-12 | 2007-03-21 | Ark Therapeutics Ltd | Production of vectors |
| EP2307551B1 (en) | 2008-06-18 | 2016-12-14 | Oxford BioMedica (UK) Limited | Purification of retroviral vectors |
| US20110008894A1 (en) | 2009-07-07 | 2011-01-13 | Cayla | Lyophilized plasmid/dna transfection reagent carrier complex |
| US8580554B2 (en) | 2009-07-31 | 2013-11-12 | Baxter International Inc. | Method of producing a polypeptide or virus of interest in a continuous cell culture |
| WO2011097447A2 (en) * | 2010-02-04 | 2011-08-11 | Neurologix, Inc. | Production of recombinant virus |
| CA2823639A1 (en) | 2011-01-05 | 2012-07-12 | Expression Therapeutics, Llc | High yield suspension cell line, system, and method for making same |
| EP2782997B1 (en) | 2011-11-24 | 2018-01-10 | Genethon | Scalable lentiviral vector production system compatible with industrial pharmaceutical applications |
-
2012
- 2012-11-26 EP EP12795778.5A patent/EP2782997B1/en not_active Revoked
- 2012-11-26 JP JP2014542880A patent/JP6280869B2/ja not_active Expired - Fee Related
- 2012-11-26 AU AU2012342355A patent/AU2012342355B2/en not_active Ceased
- 2012-11-26 SI SI201231258T patent/SI2782997T1/en unknown
- 2012-11-26 US US14/359,960 patent/US20140315294A1/en not_active Abandoned
- 2012-11-26 HU HUE12795778A patent/HUE036742T2/hu unknown
- 2012-11-26 BR BR112014012600A patent/BR112014012600A2/pt not_active Application Discontinuation
- 2012-11-26 CN CN201810811238.0A patent/CN109097398A/zh active Pending
- 2012-11-26 RS RS20180365A patent/RS57066B1/sr unknown
- 2012-11-26 LT LTEP12795778.5T patent/LT2782997T/lt unknown
- 2012-11-26 EP EP17210574.4A patent/EP3327119A1/en not_active Withdrawn
- 2012-11-26 CN CN201280058157.9A patent/CN104136605B/zh not_active Expired - Fee Related
- 2012-11-26 PL PL12795778T patent/PL2782997T3/pl unknown
- 2012-11-26 SG SG11201402584RA patent/SG11201402584RA/en unknown
- 2012-11-26 PT PT127957785T patent/PT2782997T/pt unknown
- 2012-11-26 HR HRP20180424TT patent/HRP20180424T1/hr unknown
- 2012-11-26 DK DK12795778.5T patent/DK2782997T3/en active
- 2012-11-26 CA CA2856455A patent/CA2856455C/en active Active
- 2012-11-26 ES ES12795778.5T patent/ES2663815T3/es active Active
- 2012-11-26 SM SM20180174T patent/SMT201800174T1/it unknown
- 2012-11-26 WO PCT/EP2012/073645 patent/WO2013076309A1/en active Application Filing
-
2017
- 2017-10-05 JP JP2017195148A patent/JP2018046828A/ja active Pending
-
2018
- 2018-03-30 CY CY20181100358T patent/CY1120103T1/el unknown
-
2019
- 2019-03-18 US US16/356,005 patent/US20190211360A1/en not_active Abandoned
-
2021
- 2021-09-02 US US17/464,727 patent/US20220235371A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| ES2663815T3 (es) | 2018-04-17 |
| CN104136605B (zh) | 2018-08-14 |
| EP2782997A1 (en) | 2014-10-01 |
| CN109097398A (zh) | 2018-12-28 |
| EP3327119A1 (en) | 2018-05-30 |
| CA2856455C (en) | 2022-08-23 |
| SG11201402584RA (en) | 2014-06-27 |
| JP2018046828A (ja) | 2018-03-29 |
| DK2782997T3 (en) | 2018-04-16 |
| JP6280869B2 (ja) | 2018-02-14 |
| PL2782997T3 (pl) | 2018-06-29 |
| WO2013076309A1 (en) | 2013-05-30 |
| RS57066B1 (sr) | 2018-06-29 |
| LT2782997T (lt) | 2018-05-25 |
| HRP20180424T1 (hr) | 2018-06-29 |
| CA2856455A1 (en) | 2013-05-30 |
| JP2014533516A (ja) | 2014-12-15 |
| US20220235371A1 (en) | 2022-07-28 |
| AU2012342355A1 (en) | 2014-07-17 |
| US20190211360A1 (en) | 2019-07-11 |
| EP2782997B1 (en) | 2018-01-10 |
| BR112014012600A2 (pt) | 2017-06-06 |
| CN104136605A (zh) | 2014-11-05 |
| SMT201800174T1 (it) | 2018-07-17 |
| AU2012342355B2 (en) | 2017-10-12 |
| PT2782997T (pt) | 2018-04-09 |
| US20140315294A1 (en) | 2014-10-23 |
| CY1120103T1 (el) | 2018-12-12 |
| HUE036742T2 (hu) | 2018-07-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SI2782997T1 (en) | A rolling lentiviral vector manufacturing system compatible with industrial pharmaceutical applications | |
| AU2020368539A1 (en) | Engineered muscle targeting compositions | |
| AU2022287660B2 (en) | Rapamycin resistant cells | |
| Schweizer et al. | Large-scale production means for the manufacturing of lentiviral vectors | |
| US20210180091A1 (en) | Materials and methods for treatment of hemoglobinopathies | |
| CN109415415B (zh) | 用于衣壳化基因组工程系统的颗粒 | |
| US11371059B2 (en) | Viral particle for the transfer of RNAs, especially into cells involved in immune response | |
| ES2973118T3 (es) | Bio-producción de vectores lentivirales | |
| Marin et al. | RD-MolPack technology for the constitutive production of self-inactivating lentiviral vectors pseudotyped with the nontoxic RD114-TR envelope | |
| US20200149065A1 (en) | Foamy viral vector compositions and methods for the manufacture of same | |
| KR20240035852A (ko) | 벡터 제조 프로세스 | |
| CN116323934A (zh) | 生产临床级慢病毒载体的方法 | |
| CN115836130A (zh) | 聚乙烯亚胺-脱氧核糖核酸复合物大小和活性的稳定化 | |
| McCarron et al. | Scale-up of lentiviral vectors for gene therapy: advances and challenges | |
| US11066678B2 (en) | Methods of improving titer in transfection-based production systems using eukaryotic cells | |
| JP2021533826A (ja) | 正確に改変した秘匿メッセンジャーｒｎａ、及び、その他のポリヌクレオチド | |
| Nilsson | Process development of lentiviral vector expression, purification and formulation for gene therapy applications | |
| CN113039270A (zh) | 用于蛋白质制造的载体 | |
| Borovikova et al. | Efficient Genome Editing Using ‘NanoMEDIC’AsCas12a-VLPs Produced with Pol II-Transcribed crRNA | |
| Perry | Lentiviral vector stability and process purification based on modifications to the viral envelope | |
| WO2021234455A2 (en) | Promoter sequences for in vitro and in vivo expression of gene therapy products in cd3+ cells | |
| Park | Optimizing Growth and Productivity of Mammalian Cells for Immunotherapeutic Applications | |
| WO2023230675A1 (en) | Method, use, and kit relating to an rna virus | |
| CN119562820A (zh) | 制造病毒颗粒 | |
| WO2013146480A1 (ja) | 遺伝子導入方法 |